Senior Director, Commercialization FP&A
Revolution Medicines
Summary
Revolution Medicines is seeking a Senior Director of Commercialization FP&A to join our growing Finance team. The Senior Director of Commercialization FP&A will act as the key financial business partner for our growing Global Commercialization organization and support Global Commercial & Access, Global Medical Affairs, and US Commercial teams. This role reports to the VP, FP&A.
Job description
Responsibilities
- Build and maintain strong cross-functional business partnerships to forecast and track activities by embedding finance into decision-making processes.
- Collaborate with various levels of management to gather, analyze, summarize, and prepare operating budgets and financial forecasts during planning cycles (e.g., annual budget, mid-year re-forecast, launch planning, etc.).
- Provide financial direction to key stakeholders with influence with proactive recommendations, supported by robust financial analysis and insightful delivery.
- Develop and prepare monthly internal financial management reporting packages and commercialization profit/loss reports for the global and US organizations, closely working with ex-US Finance colleagues to streamline overall approach and business rules across different regions.
- Oversee monthly variance analysis of actuals to budget, investigate any major discrepancies, and articulate key business drivers.
- Support ad hoc analyses and special projects, providing timely and accurate financial insights to support successful commercialization of medicines upon regulatory approval.
- Help drive process improvements and efficiencies in areas of financial planning, financial analysis, and production of reporting packages.
Required Skills, Experience and Education
- Bachelor's degree in Finance, Accounting, or related field.
- CPA or MBA preferred.
- 12+ years in biopharmaceuticals finance/FP&A with progressive leadership roles.
- 5+ years of managerial experience.
- Experience with commercial product launch and global expansion preferred.
- Working knowledge of GAAP.
- Excel expertise with modeling experience, PowerPoint proficiency.
- Extensive experience utilizing financial systems and other business intelligence tools.
- Strong written and oral communication skills.
- Strong analytical thinking and attention to detail and accuracy.
- Strong collaboration skills to work cross-functionally with ability to synthesize viewpoints of different functions, while executing on individual and shared goals.
Requirements
- Bachelor's degree in Finance, Accounting, or related field.
- CPA or MBA preferred.
- 12+ years in biopharmaceuticals finance/FP&A with progressive leadership roles.
- 5+ years of managerial experience.
- Experience with commercial product launch and global expansion preferred.
- Working knowledge of GAAP.
- Excel expertise with modeling experience, PowerPoint proficiency.
- Extensive experience utilizing financial systems and other business intelligence tools.
- Strong written and oral communication skills.
- Strong analytical thinking and attention to detail and accuracy.
- Strong collaboration skills to work cross-functionally with ability to synthesize viewpoints of different functions, while executing on individual and shared goals.
Benefits
- Competitive cash compensation
- Equity awards
- Learning and development opportunities
Company overview
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. The company is pioneering a new class of therapeutics that target oncogenic RAS mutations, which are among the most common drivers of human cancers. Revolution Medicines employs a unique approach to drug discovery, leveraging deep insights into RAS biology to develop small molecule inhibitors that can address previously undruggable targets. Their pipeline includes multiple clinical-stage candidates designed to inhibit various RAS pathway mutations, with a particular focus on KRAS G12C and other RAS variants. The company's scientific platform combines structural biology, medicinal chemistry, and computational approaches to design highly selective inhibitors. Revolution Medicines aims to transform cancer treatment by developing therapies that can overcome resistance mechanisms and provide durable clinical benefits for patients with RAS-driven malignancies. Their research represents a significant advancement in the field of targeted cancer therapy, addressing one of the most challenging areas in oncology drug development.